FogPharma Secures $66 Million Series B Financing

Company is pioneering a powerful new class of medicines - cell-penetrating miniproteins - with an on-demand drug discovery platform for the treatment of serious diseases driven by intractable targets BOSTON, May 16, 2018 -- (Healthcare Sales & Marketing... Biopharmaceuticals, Venture Capital, Personnel FogPharma, miniprotein
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news